Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Christopher M Starr is Director at Monopar Therapeutics. OQRO lists 6 transactions filed with the SEC under this name, the latest on Oct 6, 2026, each linked to the official Form 4.
Director
Disclosures on record
6
Companies involved
1
As of the latest filing on , Christopher M Starr reported holding 5,173 shares of Monopar Therapeutics (MNPR), worth about $357K at the last close of $69 (Nov 20, 2026). In the last 12 months, Christopher M Starr sold $659K in 3 sales.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Monopar Therapeutics MNPR | 5,173 | 5,173 direct | $69 | $357K | Oct 1, 2026 |
Is this Christopher M Starr’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Monopar TherapeuticsMNPR
6 disclosures · Jul 2025 – Oct 2026 · 4 sold
Oct 1, 2026Sold~$362Kdisclosed Oct 6
DetailsOfficial recordOct 1, 2026Sold~$234Kdisclosed Oct 6
DetailsOct 1, 2026Sold~$64Kdisclosed Oct 6
DetailsOfficial recordOct 1, 20268,400disclosed Oct 6
DetailsOfficial recordOct 1, 20268,400disclosed Oct 6
DetailsOfficial recordJul 14, 2025Sold~$672Kdisclosed Jul 17
DetailsOfficial recordChristopher M Starr has no open-market purchase on record since 2025. Sales in 2 of the 2 years since 2025.
Christopher M Starr reported 0 open-market purchases and 4 sales since 2025; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $659K3×3 trades |
| 2025 | — | $672K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Oct 1, 2026, Christopher M Starr reported holding 5,173 shares of Monopar Therapeutics (MNPR). At the last close of $69 on Nov 20, 2026, that is about $357K. This is the stake disclosed in filings, not a net worth.
No public filing gives Christopher M Starr's net worth. What SEC Form 4 shows is the stock stake: 5,173 shares of Monopar Therapeutics (MNPR), about $357K at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
In SEC filings of the last 12 months, Christopher M Starr reported 3 open-market sales worth $659K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Christopher M Starr has no open-market purchase on record since 2025. Sales in 2 of the 2 years since 2025.
In SEC filings since 2025: no open-market purchase is on record; the latest open-market sale is from 2026.
Monopar Therapeutics (MNPR), from 2025 to 2026: 0 purchases and 4 sales.
Christopher M Starr reported 0 open-market purchases and 4 sales here, 2025 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.